Viral Vectors and Vaccines
Bioprocessing Group
Home
People
Research
Resources
Publications
Contact
Amine A. Kamen
Latest
Critical Assessment of Purification and Analytical Technologies for Enveloped Viral Vector and Vaccine Processing and Their Current Limitations in Resolving Co-Expressed Extracellular Vesicles
Vectored-Vaccine Platforms Enabled Rapid Development of Safe and Effective Vaccines in Response to COVID-19 Pandemic Situation
Recent advances and current challenges in process intensification of cell culture-based influenza virus vaccine manufacturing
Characterization of Extracellular Vesicles Secreted in Lentiviral Producing HEK293SF Cell Cultures
Bioreactor production of rVSV-based vectors in Vero cell suspension cultures
Cross-Validation of ELISA and a Portable Surface Plasmon Resonance Instrument for IgG Antibodies Serology with SARS-CoV-2 Positive Individuals
Advancements in molecular design and bioprocessing of recombinant adeno-associated virus gene delivery vectors using the insect-cell baculovirus expression platform
Rapid High-Yield Production of Functional SARS-CoV-2 Receptor Binding Domain by Viral and Non-Viral Transient Expression for Pre-Clinical Evaluation
Vero cell upstream bioprocess development for the production of viral vectors and vaccines
A pooled genome-wide screening strategy to identify and rank influenza host restriction factors in cell-based vaccine production platforms
Establishing a Robust Manufacturing Platform for Recombinant Veterinary Vaccines: An Adenovirus-Vector Vaccine to Control Newcastle Disease Virus Infections of Poultry in Sub-Saharan Africa
Titration methods for rVSV-based vaccine manufacturing
Serum-free production of rVSV-ZEBOV in Vero cells: microcarrier bioreactor versus scale-X™ hydro fixed-bed
Lentiviral Vector Production in Suspension Culture Using Serum-Free Medium for the Transduction of CAR-T Cells
Production of rVSV-ZEBOV in serum-free suspension culture of HEK 293SF cells
Cite
×